Amgen submits MAA for novel investigational LDL cholesterol-lowering medication evolocumab
Amgen announced submission of a Marketing Authorization Application to the EMA for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9. September 02, 2014